FDA says M & M Beauty and Wellness sells an unapproved, misbranded hydroquinone skin-lightening cream.
What happened
FDA reviewed the label of BEST age spot remover lightening perfection crème and the company's website, www.mandmbeautyandwellness.com, rather than conducting an inspection. The label and website present the cream, which contains 2% hydroquinone, as a skin lightener for freckles, age spots and liver spots. Because FDA had already proposed that over-the-counter skin bleaching products are not generally recognized as safe and effective, the agency says the product has needed an approved new drug application since September 23, 2020, and has none.
What FDA found
The cream is a drug because it is sold to lighten skin and treat spots, which is meant to affect how the body looks or works.
Section 201(g)(1)(B) and (C) of the FD&C Act, 21 U.S.C. 321(g)(1)(B) and (C)The company sells the cream without an FDA-approved new drug application.
Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)FDA has proposed that over-the-counter skin bleaching products, including those with hydroquinone, are not generally recognized as safe and effective, so this product needed approval after September 23, 2020.
Section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4)The product is misbranded because it is an unapproved nonprescription drug that does not meet the requirements for marketing without approval.
Section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)Shipping an unapproved or misbranded drug across state lines is prohibited.
Sections 301(a) and (d) of the FD&C Act, 21 U.S.C. 331(a) and (d)
What FDA wants
FDA asks the company to respond in writing within 15 working days to the Office of Unapproved Drugs and Labeling Compliance at FDAADVISORY@fda.hhs.gov, saying what it has done to fix the violations and prevent them from recurring, or explaining why more time is needed.
Who should pay attention
- online sellers of skin-lightening and dark-spot creams
- companies making or repackaging hydroquinone skin products
- distributors and retailers that buy small-brand skin care
This is a summary. Read the original letter on fda.gov.